Your browser doesn't support javascript.
loading
Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study.
Ogawa, Yuji; Kobayashi, Takashi; Honda, Yasushi; Kessoku, Takaomi; Tomeno, Wataru; Imajo, Kento; Nakahara, Takashi; Oeda, Satoshi; Nagaoki, Yuko; Amano, Yuichiro; Ando, Tatsuya; Hirayama, Megumi; Isono, Osamu; Kamiguchi, Hidenori; Nagabukuro, Hiroshi; Ogawa, Shinji; Satomi, Yoshinori; Saigusa, Yusuke; Takahashi, Hirokazu; Hyogo, Hideyuki; Yoneda, Masato; Saito, Satoru; Yamanaka, Takeharu; Aishima, Shinichi; Eguchi, Yuichiro; Kage, Masayoshi; Chayama, Kazuaki; Nakajima, Atsushi.
Afiliación
  • Ogawa Y; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kobayashi T; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Honda Y; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kessoku T; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Tomeno W; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Imajo K; Department of Gastroenterology, International University of Health and Welfare Atami Hospital, Atami, Japan.
  • Nakahara T; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Oeda S; Department of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Nagaoki Y; Liver Center, Saga University Hospital, Saga, Japan.
  • Amano Y; Department of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Ando T; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Hirayama M; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Isono O; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Kamiguchi H; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Nagabukuro H; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Ogawa S; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Satomi Y; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Saigusa Y; Research, Takeda Pharmaceutical Company, Yokohama, Japan.
  • Takahashi H; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
  • Hyogo H; Liver Center, Saga University Hospital, Saga, Japan.
  • Yoneda M; Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan.
  • Saito S; Department of Gastroenterology and Hepatology, JA Hiroshima General Hospital, Hiroshima, Japan.
  • Yamanaka T; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Aishima S; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Eguchi Y; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
  • Kage M; Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Japan.
  • Chayama K; Liver Center, Saga University Hospital, Saga, Japan.
  • Nakajima A; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan.
Hepatol Res ; 50(8): 955-965, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32455496
ABSTRACT

AIM:

Liver biopsy is still required for the diagnosis of hepatocellular ballooning and inflammation, which are important histological features of non-alcoholic steatohepatitis. We undertook this multicenter, cross-sectional study to identify novel blood markers for the diagnosis of hepatocellular ballooning.

METHODS:

We enrolled 176 patients, of whom 132 were proven by liver biopsy as having non-alcoholic fatty liver disease (NAFLD) and classified as non-ballooning (ballooning grade 0) (n = 83) or ballooning (ballooning grade 1 and 2) (n = 49) by a central pathology review. We carried out gas chromatography-mass spectrometry, hydrophilic interaction liquid chromatography tandem mass spectrometry, and lipidomics with plasma.

RESULTS:

As correlates of hepatocellular ballooning, among the clinical parameters, serum type IV collagen 7S correlated most significantly with the ballooning grade (correlation coefficient [CC] = 0.463; P < 0.001). Among the metabolic/lipidomic markers, phosphatidylcholine (PC) (aa-448) correlated most significantly with the ballooning grade (CC = 0.394; P < 0.001). The area under the receiver operating characteristic curve of type IV collagen 7S, choline, and lysophosphatidylethanolamine (LPE) (e-182), was 0.846 (95% confidence interval, 0.772-0.919).

CONCLUSIONS:

Plasma levels of PC were positively correlated, and those of lysophosphatidylcholine and LPE were negatively correlated with hepatocellular ballooning in NAFLD patients. These non-invasive metabolic/lipidomic-based plasma tests might be useful to distinguish between cases of NAFLD with and without hepatocellular ballooning.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Idioma: En Revista: Hepatol Res Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Idioma: En Revista: Hepatol Res Año: 2020 Tipo del documento: Article País de afiliación: Japón